Related references
Note: Only part of the references are listed.Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials
Marjolijn Duijvestein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Interrogating host immunity to predict treatment response in inflammatory bowel disease
Jonathan L. Digby-Bell et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure
Thomas Chateau et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Head-to-head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences
M. T. Wan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review
Dong Yeon Jeong et al.
AUTOIMMUNITY REVIEWS (2019)
Most noninferiority trials were not designed to preserve active comparator treatment effects
Michael Tsui et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
Bram Verstockt et al.
EBIOMEDICINE (2019)
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
Jenna L. Koliani-Pace et al.
INFLAMMATORY BOWEL DISEASES (2019)
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
Parambir S. Dulai et al.
GASTROENTEROLOGY (2019)
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Bruce E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development
Walter Reinisch et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Differences in Outcomes Reported by Patients With Inflammatory Bowel Diseases vs Their Health Care Professionals
Valerie E. H. Pittet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Big data in IBD: a look into the future
Pablo Olivera et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
New biologics and small molecules in inflammatory bowel disease: an update
Joao Sabin et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis
C. Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey
P. Olivera et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab
Lieven Pouillon et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review
Christopher Ma et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Population Health Management for Inflammatory Bowel Disease
Parambir S. Dulai et al.
GASTROENTEROLOGY (2018)
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease
Silvio Danese et al.
GASTROENTEROLOGY (2018)
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease
Geert D'Haens et al.
GASTROENTEROLOGY (2018)
Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data
Brian Feagan et al.
INFLAMMATORY BOWEL DISEASES (2018)
OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
D Faleck et al.
Journal of Crohns & Colitis (2018)
Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness
Jacqueline Corrigan-Curay et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Meta-analysis and the science of research synthesis
Jessica Gurevitch et al.
NATURE (2018)
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Lawrence Blonde et al.
ADVANCES IN THERAPY (2018)
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Network meta-analysis: an introduction for clinicians
Benjamin Rouse et al.
INTERNAL AND EMERGENCY MEDICINE (2017)
Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations
Laurent Peyrin-Biroulet et al.
JOURNAL OF CROHNS & COLITIS (2017)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel et al.
LANCET (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial
Cyriel Y. Ponsioen et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus
L. Vuitton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials
L. Vuitton et al.
GUT (2016)
Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up
Robert V. Bryant et al.
GUT (2016)
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases
Subrata Ghosh et al.
INFLAMMATORY BOWEL DISEASES (2016)
The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses
John P. A. Ioannidis
MILBANK QUARTERLY (2016)
Review of head-to-head study designs in rheumatoid arthritis
R. Fleischmann et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial
John G. Williams et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
W. J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor
Maria Elena Flacco et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2015)
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna et al.
LANCET (2015)
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Brian G. Feagan et al.
GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
Stephane Paul et al.
INFLAMMATORY BOWEL DISEASES (2014)
Blinding in pharmacological trials: the devil is in the details
Mandy Wan et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2013)
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
Michael E. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2013)
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
Christina Ha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease
Geert D'Haens et al.
GASTROENTEROLOGY (2012)
Methods in Comparative Effectiveness Research
Katrina Armstrong
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
David Laharie et al.
LANCET (2012)
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial
Volker Gross et al.
JOURNAL OF CROHNS & COLITIS (2011)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
Industry sponsorship and selection of comparators in randomized clinical trials
D. N. Lathyris et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of Extended MMX Mesalamine Therapy for Acute, Mild-to-Moderate Ulcerative Colitis
Michael A. Kamm et al.
INFLAMMATORY BOWEL DISEASES (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
Michael A. Kamm et al.
GASTROENTEROLOGY (2007)
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
L Durelli et al.
LANCET (2002)
Blinding in randomised trials: hiding who got what
KF Schulz et al.
LANCET (2002)
Share Paper
